PDF(Pubmed)
Abstract：
Treatment of Mycobacterium abscessus infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects. Select dual beta-lactam combinations, with or without beta-lactamase inhibitors, have been shown to be highly active in vitro. Herein, we describe a 6-year-old child with underlying mild bilateral lower lobe cylindrical bronchiectatic lung disease who developed pulmonary Mycobacterium abscessus infection and was treated with a multi-drug regimen including two β-lactam antibiotics, achieving both early clinical and microbiological cure. This case highlights the potential benefit of dual β-lactam therapy for the treatment of drug-resistant Mycobacterium abscessus infection.
摘要：
脓肿分枝杆菌感染的治疗提出了重大挑战，大环内酯耐药菌株的出现加剧了这种情况，这些菌株需要联合使用多种抗菌剂，并具有明显的毒性作用。选择双β-内酰胺组合，有或没有β-内酰胺酶抑制剂，已被证明在体外具有很高的活性。在这里，我们描述了一名6岁儿童，患有潜在的轻度双侧下叶圆柱形支气管扩张肺病，他发展了肺脓肿分枝杆菌感染，并接受了包括两种β-内酰胺抗生素在内的多药方案治疗。实现早期临床和微生物治愈。该病例强调了β-内酰胺双重疗法治疗耐药脓肿分枝杆菌感染的潜在益处。
